ZYPADHERA is an injectable form for prolonged liberation of Olanzapine, an atypical second generation antipsychotic. Administered as an intramuscular, it is indicated in the treatment of support for schizophrenic adult patients already stabilized with the oral form. In some cases, it is also prescribed for the management of bipolar disorders or resistant depressions, when other therapeutic options have not provided sufficient results. This treatment requires only an injection every two to four weeks, which improves the support of patients often unstable to their treatment. Conversely, the oral form requires daily intake, with an increased risk of interruption which can cause a relapse or decompensation.
Production difficulties and quality defects
Since May 2024, the CHEPLAPHARM laboratory, which manufactures the ZYPADHERA, has encountered supply problems in Europe. These difficulties, first temporary, worsened in the year 2025. The ANSM explains that it was “informed by the CHEPLAPHARM laboratory of supplies of supplies in ZYPADHERA, linked to additional manufacturing and supply chain difficulties on its production site”. The agency also specifies that “two lots could not be marketed due to a quality defect, which accentuates tensions (…)
Read more on top health
Eat these 10 foods every day and lose up to 2 kg in a month, according to a renowned nutritionist
Charlotte Gainsbourg’s free tip for beautiful skin: “It would be the youth secret of the Japanese”
Healthy diets: here is the frequent error that limits your results, according to a study published in Nature Medecine
The only thing to do every day if you want to reduce your LDL cholesterol, according to cardiologists
Do you suffer from kneeling pain? Here are 5 exercises to do at home, recommended by physiotherapists